News

The continued collaboration strengthens the ongoing partnership between the two companies, focusing on the discovery of novel treatments for tropical and neurological diseases at Eisai's 14.5 acre, state-of-the-art

Sanfilippo A is also known as Mucopolysaccharidosis Type IIIA (MPS IIIA). SAMOS is particularly important as there is currently no validated biomarker in MPS IIIA that reflects CNS

Scientists at Sheffield University’s Institute of Translational Neuroscience (SITraN) believe the drug has demonstrated the potential to prevent the death of motor neurones and stop the onset of the

The CRL does not require Sunovion to conduct any additional clinical studies for the approval of SUN-101/eFlow. Sunovion will work with the FDA to determine an appropriate path

This voluntary recall follows a report that a professional sample bottle containing eight tablets of BRILINTA 90mg also contained another medicine called ZURAMPIC (lesinurad) 200mg tablets which is

The recommendation covers the drug as therapy for NETs that are well- or moderately-differentiated, unresectable or metastatic, and of pancreatic origin in patients with progressive disease. Afinitor has

Changes in tau are associated with a number of diseases affecting the nervous system, including Alzheimer’s disease (AD). “Securing alliances with leading industry partners is a key part

The financing was co-led by Arix Bioscience and New Leaf Venture Partners. Mark Chin, Investment Manager at Arix, and Ron Hunt, Managing Director at New Leaf, will join

The committee has recommended the approval based on its assessment of the totality of evidence, comprising of showing comparable efficacy and safety of biosimilar epoetin alfa to its